ArticleHuman vaccines & immunotherapeutics2021
Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Observational
- Public perception of medical detection dogs and other COVID-19 testing strategies.Frontiers in public health · 2025Article
- Heterologous prime-boost vaccination drives stromal activation and adaptive immunity against SARS-CoV-2 variants.Frontiers in immunology · 2025Article
- Impact of COVID-19 Pandemic on Routine Childhood Immunization Programs in Indonesia: Taking Rural and Urban Area into Account.Patient preference and adherence · 2024Article
- Analysis on the Selection of Herbs in TCM COVID-19 Treatment Protocols Between Malaysia and China.International journal of general medicine · 2023Article
- Complete Genomic Characterisation and Mutation Patterns of Iraqi SARS-CoV-2 Isolates.Diagnostics (Basel, Switzerland) · 2022Article
- Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions.Human vaccines & immunotherapeutics · 2022Review
- Strategies and safety considerations of booster vaccination in COVID-19.Bosnian journal of basic medical sciences · 2022Review
- Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis.Frontiers in immunology · 2022Article
- Self-administered digital vaccination decision-aids in primary care: A pilot study of COVID-19 vaccination in Atlanta, GA.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Throughout the globe, many nations are struggling to cope with the consecutive waves of the COVID-19. Several vaccines have been employed to overcome this ongoing pandemic and are available as single and double-dose inoculations; however, homologous vaccine efficacy is being reconsidered due to the rapidly emerging SARS-CoV-2 variants. Many studies have been conducted on the heterologous prime-boost vaccine regimens and have shown good efficacy results against COVID-19. This article aims to highlight the safety and reliability of heterologous prime-boost vaccination against COVID-19. We have also made some recommendations towards using these combinations of vaccines for the global mitigation of the subsequent waves of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.